Determine if Medicare Part D beneficiaries who received telephone MTM services had:1) Decreased medication/health-related problems (MHRPs); 2) Improved medication adherence; and 3) Decreased total Part D drug costs when compared to a control group. METHODS: Part D beneficiaries from a Texas health plan participated. The Andersen Model was the theoretical framework. Independent variables were: predisposing factors (age, gender, and race); and need factors (number of medications and chronic diseases and medication regimen complexity (MRC). The health behavior (intervention) was MTM utilization. Outcomes were change (from baseline to 12-month follow-up) in: 1) Number of MHRPs; 2) Medication adherence measured by the medication possession ratio (MPR); and 3) Total drug costs. Descriptive and inferential statistical analyses were conducted. RESULTS: The intervention (nϭ60) and control (nϭ60) groups were not statistically different regarding age (71.2Ϯ7.5 vs.73.9Ϯ8.0), medications (13.0Ϯ3.2 vs.13.2Ϯ3.4), chronic diseases (6.5Ϯ2.3 vs.7.0Ϯ2.1) or MRC [(21.5 (range 8 -43) vs.22.8 (range 9 -42.5)], respectively. The majority (51%) were male in the intervention group but only 28% were male in the control group (pϭ0.009). At baseline, 4.8Ϯ 2.7 (intervention group) and 9.1Ϯ 2.9 (control group) MHRPs were identified and 2.2Ϯ2.0 and 7.3Ϯ3.0 MHRPs remained at the 12-month follow-up, respectively. Multivariate regression revealed that MHRPs decreased significantly (pϭ0.0120) among the intervention group when compared to the control group. There were no significant predictors of change in MPR. Total drug costs (change from baseline to follow-up) decreased by $588Ϯ$2,086 in the intervention group and increased by $207Ϯ$1,752 in the control group. A t-test indicated the cost difference between the 2 groups was significant (pϭ0.03), but the multivariate regression did not indicate significant predictors. CONCLUSIONS: A telephone MTM program positively impacted MHRPs. Unadjusted cost comparisons also showed cost savings among the intervention group. Future research should focus on understanding predictors that impact adherence and cost-related MTM outcomes. 
OBJECTIVES:
To evaluate the effect of a policy implemented in the Louisiana Medicaid program which capped reimbursement to eight prescriptions per member per month on medication persistency in patients with diabetes, hypertension, or hyperlipidemia. METHODS: A pre-post non-equivalent comparator group design was applied using Medicaid claims data from [2001] [2002] [2003] for Louisiana (LA) and Indiana (IN) to identify patients with the specified conditions and their medication persistency. Persistency was defined as the number of days to discontinuation which was identified as a gap in treatment 30 days or longer. To capture preintervention trends in medication persistency, we compared "pre-policy" cohorts in LA and IN followed for ten months prior to policy adoption (March 3, 2002 to December 31, 2002 to policy cohorts followed ten months after policy adoption (March 3, 2003 to December 31, 2003 . All incident cohorts were identified using a six-month washout period. We used Cox-proportional hazard models to compared discontinuation rates in LA and IN across the pre-policy and policy period cohorts. RESULTS: After adjusting for patient characteristics and comorbid conditions, no significant differences in persistency were found prior to policy implementation between LA and IN for any of the three chronic conditions. In the post-policy period, all cohorts had significantly lower persistency in LA than in IN. Patients in LA with diabetes and hypertension were 1.38 (pϭ 0.03) and 2.00 (pϽ0.01) times more likely to discontinue their medications at day 30 of the follow-up, respectively. The hazard ratios declined to 1.21 and 1.67 for diabetes and hypertension patients respectively after 260 days. The hazard ratio of discontinuation for patients with hyperlipidemia in LA was constantly 1.31 (pϽ0.01) across the follow-up period. CONCLUSIONS: Patients with chronic conditions subject to medication caps may be vulnerable to medication discontinuation. Policy makers need to consider carefully when implementing such policies on patients with chronic conditions. 
DM4 EVALUATION OF CLINICAL LABORATORY-PHARMACY LINKAGE DECISION SUPPORT IN THE USE OF POTASSIUM SUPPLEMENTS

OBJECTIVES:
Clinical decision support (CDS) has been utilized to link laboratory and pharmacy data to optimize medication therapy. This study aimed to evaluate the effect of synchronous and asynchronous CDS in inpatients receiving potassium supplements. METHODS: The synchronous and real-time asynchronous lab-pharmacy CDS was implemented in our 450-bed academic teaching hospital in June 2003. Non-hemolyzed serum potassium ([Kϩ]) values and medication orders for potassium supplements, 12 months prior to and after CDS implementation, were analyzed. A Cox proportional hazards model was constructed to assess the effect of CDS in improving clinicians' response time at the presence of hyperkalemia. Potassium Ն5.0 mEq/L and Ͼ5.4 mEq/L were used to define high normal and elevated hyperkalemia. Response time was measured from the time of the first instance of hyperkalemia to cancelation of the medication order. Response time was censored at the time of a consequent normal potassium or patient discharge. RESULTS: In the pre-CDS period, 12.5% (1439/11512) of the potassium supplement orders were followed by at least one abnormal serum potassium value; whereas in the post-CDS period, 10.96% (1206/11005) of the orders were alerted by CDS. While controlling for patient characteristics, posting time of the hyperkalemic results, and severity of hyperkalemia (5.0 mEq/LՅ[Kϩ]Յ5.4 mEq/L vs. [Kϩ]Ͼ5.4 mEq/L), potassium supplement orders were cancelled more rapidly after CDS implementation (hazard ratio[HR]ϭ1.14, pϭ0.007). Moreover, clinicians responded sooner if the result with hyperkalemia was posted during 6am-noon vs. midnight-6am (HRϭ1.36, pϽ0.001), while the response time was longer if the result was posted during noon-6pm (HRϭ0.73, pϭ0.004) or 6pm-Midnight (HRϭ0.57, pϽ0.001). Patient age, sex, race, and the severity of hyperkalemia had no significant effect on clinicians' response time. CONCLUSIONS: The synchronous and asynchronous real-time lab-pharmacy linkage decision support helped clinicians to manage potassium supplements in a more timely manner in patients with high normal or elevated potassium. 
PODIUM SESSION I: EMPLOYEE HEALTH & PRODUCTIVITY OUTCOMES RESEARCH
OR1 THE ASSOCIATION BETWEEN SELF-PERCEIVED COGNITIVE DIFFICULTIES AND LEVEL OF DEPRESSION AMONG EMPLOYEES WITH CURRENT DEPRESSION
OBJECTIVES:
Many facets of job performance may be impaired by depression. Impaired performance by depressed employees may be attributed to self-perceived cognitive difficulties. The goal of the current study was to assess self-perceived deficits in cognition experienced by employees with depression. METHODS: Individuals (Ն18 years of age) employed full-time with diagnosed depression (excluding bipolar disorder) completed a Web-based computer-generated 25-minute survey in February 2010 (study population identified by Harris Interactive TM ). The patient survey used the Perceived Deficits Questionnaire (PDQ) to assess self-perceived difficulties in memory, attention, planning and organization, and concentration using a 0-20 scale, where higher scores indicate greater impairment. The Patient Health Questionnaire (PHQ-9) was used to assess depression severity. The impact of depression on the PDQ scores was assessed using a trend test based on an analysis of covariance with age, gender, and PHQ-9 score as independent variables. RESULTS: A total of 1051 employees were included in the analysis (58% female, mean age 47 yrs, and 38% held professional employment). PHQ-9 scores indicated 423 (40.25%) employees with no depression symptoms, 319 (30.35%) with mild depression, 166 (15.79%) with moderate depression, 82 (7.80%) with moderately severe depression, and 61 (5.80%) with severe depression. PDQ scores showed that perceived cognitive functioning worsened progressively with increasing severity of depression symptoms (pϽ0.0001). PDQ scores showed the most impairment in the attention/concentration and planning/organization scales in the severely depressed (12.26 and 12.25 , respectively) compared with non-depressed subjects (4.45 and 3.75, respectively). CONCLUSIONS: In full-time employees experiencing depression, self-perceived cognitive difficulties worsened with increasing severity of depressive symptoms. 
OR2 ASSESSING THE RELATIONSHIP BETWEEN MEDICATION ADHERENCE AND EMPLOYEE PRODUCTIVITY
OBJECTIVES:
This study examined how adherence to prescribed medications for specific chronic conditions affects lost work time and on-the-job performance in an employed population. METHODS: Patients aged 18 to 64, with at least one of four conditions -CAD, hypertension, Type II diabetes, or depression -were identified from claims data for employees of five employers. Patients had also completed a health and productivity assessment (HPA). We conducted descriptive and regression analyses of the merged claims (12-months pre-HPA) and HPA data to assess whether medication adherence, comorbidity, health risks and other factors were associated with workplace productivity. Adherence measures included Medication Possession Ratio (MPR) and a dichotomous measure that assigned "adherent" patients with an MPR greater than 80%. RESULTS: The study population showed high rates of adherence: mean MPR ranged from 0.70 to 0.79 across conditions. Better adherence was associated with fewer lost hours due to absence for CAD patients on statin therapy and diabetes patients on statin or ACE/ARB therapy. For Diabetes patients on insulin or like treatment, those with MPRs of 0.80 or higher had higher job performance and fewer total work hours missed than individuals with MPRs lower than 0.80. Unexpectedly, better adherence by CAD patients on anti-platelet therapy was associated with poorer on-the-job performance. The presence of comorbid diseases and higher health risk status was associated with increased absence and poorer job performance across the four conditions. Those in the professional/executive job class typically had less absence from work but lower job performance. CONCLUSIONS: Despite high rates of adherence in this population, significant medication treatment effects were observed, as were consistent effects of comorbidities, health risks and job class on lost work time. Better targeting of treatment by job class for individuals with high health risks and comorbidities may help reduce health risks and improve productivity outcomes. 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4 
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